Clinically, intravenous TMP (3‒5 mg/kg) significantly lowered serum P-selectin in pediatric asthma patients (p < 0.01), with 95 % therapeutic efficacy surpassing the 70 % observed with glucocorticoids (p < 0.05).67 The gene discussed is SELP; the disease is asthma.